NCT05930301招募中不适用
Clinical Research on the Safety and Effectiveness of RT201(Tumor Antigen-specific Macrophage Tumor Vaccine) in the Treatment of Advanced Cervical Cancer
Peihua Lu1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2021年10月1日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 发起方
- 入组人数
- 12
- 试验地点
- 1
- 主要终点
- The objective remission rate assessed by the independent review committee according to RECIST1.1.
研究概览
简要总结
This clinical study will include tumor patients in strict accordance with the inclusion and exclusion criteria set in this clinical study, and carry out tumor-specific antigen screening, HLA typing, blood sample collection, cell separation, cell culture and cell reinfusion according to the SOP of Suzhou Ruotai RT201 Cell Therapy. According to the efficacy evaluation criteria set in this clinical study, the included patients will be evaluated and followed up for a long time, and the original data will be saved to provide real and effective clinical data for the safety and efficacy of RT201 tumor single-target individualized clinical treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Adult female patients (≥18 years old);
- •The patient himself voluntarily signed the "informed consent form";
- •HPV positive advanced cervical cancer (refer to FIGO standard);
- •Patients with persistent metastasis or recurrence of squamous cell or non-squamous cell need to be confirmed by histology or cytology;
- •Patients who have received surgical treatment or other standard first-line treatment or patients who cannot receive surgical treatment/chemotherapy/radiotherapy;
- •Physical condition is good: KPS≥70;
- •The estimated survival time is ≥3 months;
- •Have not received any treatment that may affect the evaluation of curative effect in the past 3 months;
- •The functions of liver, kidney and bone marrow are basically normal: HCT > 25%, white blood cell range 3.5-9.5×109/L, hemoglobin (Hb)≥90g, lymphocyte+monocyte > 20%; Blood Cr≤1.5×UNL (the upper limit of normal) and blood BIL ≤ 1.5× UNL; ALT and AST≤1.5×UNL (for patients with liver metastasis, ALT and ast ≤ 5.0× UNL);
- •Women of childbearing age (15-49 years old) must have a pregnancy study within 7 days before starting treatment and the results are negative; Fertile patients must agree to use effective contraceptive measures to ensure that they are not pregnant during the study period and within 3 months after stopping treatment.
排除标准
- •Patients with central nervous system (CNS) metastasis or active CNS injury (i.e., imaging instability and symptomatic injury) (except patients with a single metastatic focus who are stable after treatment);
- •Within 4 weeks before the start of cell infusion, those who have received other anti-tumor treatments, taken corticosteroids (or analogues) or used systemic treatments that affect the immune system;
- •Blood pregnancy test positive or lactating female patients;
- •Uncontrolled accompanying diseases and active infectious diseases;
- •Patients who need anticoagulant therapy (warfarin or heparin);
- •The patient was allergic to naproxen, ibuprofen, trimetazidine/sulfamethoxazole and ampicillin.
- •Have a history of bone marrow transplantation or organ transplantation.
- •Patients who have previously used gene therapy drugs;
- •Patients with the following previous diseases or accompanying diseases:a) Patients who have been diagnosed as serious autoimmune diseases need systemic immunosuppressants (steroids) for a long time (more than 2 months) or immune-mediated symptomatic diseases, including ulcerative colitis, Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus (SLE) and autoimmune vasculitis (for example, Wegener's granulomatosis;b) Patients previously diagnosed with motor neuron disease caused by autoimmune disease; c) Patients with toxic epidermal necrolysis (TEN) in the past; d) Patients suffering from any mental illness, including dementia and mental state changes, which may affect informed consent and the understanding and performance of relevant questionnaires;e) It is determined that patients with serious uncontrollable diseases may be affected by this study; f) Patients with active malignant tumors such as basal or squamous skin cancer, superficial bladder cancer and breast cancer in situ in the past 5 years who have been completely cured and do not need follow-up treatment are not included;
- •Patients who have used immunotherapy for cancer in the past 6 months include: CIK, DC, DC-CIK, LAK and other lymphocyte-based immunotherapy patients;
- •Active/chronic human immunodeficiency virus (HIV), syphilis serological positive, active hepatitis B (hepatitis B surface antigen (HBsAg) positive and hepatitis B virus (HBV) deoxyribonucleic acid (DNA) > 500IU/ml or the lower detection limit of the research center [only when the lower detection limit of the research center is higher than 500 iu/ml]), or hepatitis C virus antibody positive;
- •Have a clear history of drug allergy or an allergic constitution; Patients participating in other clinical trials at the same time Other circumstances in which the researcher thinks that the patient should not participate in this experimental study.
结局指标
主要结局
The objective remission rate assessed by the independent review committee according to RECIST1.1.
时间窗: The time from the first administration to the first observation of disease recurrence or death of the patient was evaluated for up to 36 weeks.
Main efficacy indicators
次要结局
- Disease control rate (DCR)(The percentage of subjects who reached CR, PR and SD after treatment was analyzed.No more than 36 weeks.)
- Progression-free survival (PFS)(The time interval between the patient's first treatment and the first record of disease progression or death.No more than 36 weeks.)
研究者
Peihua Lu
Principle Investigator
Wuxi People's Hospital
研究点 (1)
Loading locations...
相似试验
终止
不适用
Multi-Center Traditional Feasibility Study of Radiofrequency DeviceBody FatNCT04584099Cynosure, Inc.12
已完成
2 期
Study of GSK2132231A Antigen-Specific Cancer Immunotherapeutic in Patients With Inoperable Metastatic Cutaneous MelanomaMelanomaNCT00896480GlaxoSmithKline24
招募中
2 期
Efficacy of N-acetylcysteine in Preventing Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients.Oral Mucositis (Ulcerative) Due to RadiationNCT06354712Mansoura University50
招募中
4 期
Clinical Study on PEG-rhG-CSF in Mobilizing Autologous Hematopoietic Stem CellsLymphomaNCT06026995Chongqing University Cancer Hospital174
已完成
不适用
Multi-Center Pivotal Study of Radiofrequency DeviceBody FatNCT04569253Cynosure, Inc.65